leisure time -WSS

leisure time

author：leisure time 2025-09-27 09:46:51 - browse：9

Photo illustration of Fyodor Urnov surrounded by DNA strands. -- health coverage from STAT — Christine Kao/STAT

Researchers attending gene therapy meetings over the past couple years were liable to bump into a svelte, graying scientist explaining in emphatic, Russian-inflected English that the U.S. was wasting the grand potential of CRISPR gene editing.

Fyodor Urnov, the scientist in question, estimates he gave the talk 30 to 40 times: to fellow researchers, pharma executives, Food and Drug Administration officials, congressional staff, journalists, patient advocates. “Anyone who would listen,” he says.

The problem was one of scale. Sure, for-profit companies were developing cures for a small handful of genetic diseases, such as sickle cell disease. But there were hundreds of devastating conditions that CRISPR might be able to cure but that no entity was seriously working on.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： FDA clears Verve to begin U.S. study of gene

entertainment

WSS

FDA clears Verve to begin U.S. study of gene

Cigna wins case to block Amy Bricker's move to CVS

Curing rare childhood diseases will falter unless Congress steps up

Readers discuss the intersection of pregnancy and addiction

STAT Summit: Ending the crisis of Black deaths in the U.S.

STAT Summit: The economic case for universal basic health care

focus

leisure time

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Apple is now the first public company to be valued at $3 trillion

STAT Summit: How researchers deal with rejection

Activists slam private health insurers over coverage restrictions

UnitedHealth, Optum discontinue NaviHealth name

Activists slam private health insurers over coverage restrictions

Smaller biotechs seek to piggyback on weight loss drug boom

Medical records are filled with copy

Why a market frenzy over new weight loss drugs defies logic

knowledge

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Pharma companies must ensure equitable access to obesity drugs

STAT Readout Newsletter: Biotech news today

Roche drug slashes death risk in early

focus

entertainment

leisure time

knowledge